Clinical trial · Interventional
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)
NCT01046487CI-TRIAL-00105434PALANGI3completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Procedure | — | UNRESOLVED |
| Imatinib mesylate, Cyclophosphamide (Dosing level 1 ) | Drug | — | UNRESOLVED |
| Imatinib mesylate, Cyclophosphamide (Dosing level 2) | Drug | — | UNRESOLVED |
| Imatinib mesylate, Cyclophosphamide (Dosing level 3) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- For safety: NCI-CTCAE scale version 3.0
- timeFrame
- 42 days
Secondary outcomes (1)
- measure
- For anti tumoral efficiency : RECIST criteria
- timeFrame
- 70 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Rare tumor * metastatic disease or locally advanced disease, inoperable, with no standard treatment * At least 28 days since the prior treatment * Measurable disease with at least one measurable lesion Exclusion Criteria: * Medullary insufficiency * Cystitis, haemorrhagic cystitis * Hepatic porphyria
References
Publications (0)
Data not yet available
No reference posted for this study.